Cartesian Therapeutics
RNAC
101 hedge funds and large institutions have $219M invested in Cartesian Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 15 closing their positions.
355% more call options, than puts
Call options by funds: $2.89M | Put options by funds: $635K
31% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 29
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 98 → 101 (+3)
0.06% less ownership
Funds ownership: 1.61% → 1.54% (-0.06%)
11% less capital invested
Capital invested by funds: $245M → $219M (-$26M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cetera Advisors
Denver,
Colorado
|
+$2.83M |
| 2 |
SG Americas Securities
New York
|
+$2.74M |
| 3 |
BlackRock
New York
|
+$1.78M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.41M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$12.6M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.39M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.73M |
| 4 |
Goldman Sachs
New York
|
-$2.03M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
101
OrbiMed
New York
| – | -$1.53M | -11,306 | Closed |
|
102
California Public Employees Retirement System
Sacramento,
California
| – | -$643K | -4,737 | Closed |
|
|
LCM
103
Laurion Capital Management
New York
| – | -$453K | -3,333 | Closed |
|
104
D.E. Shaw & Co
New York
| – | -$323K | -2,379 | Closed |
|
|
WIA
105
Wealthstreet Investment Advisors
Dallas,
Texas
| – | -$167K | -1,233 | Closed |
|
106
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$151K | -1,114 | Closed |
|
|
SM
107
SG3 Management
Dorado,
Puerto Rico
| – | -$113K | -833 | Closed |
|
|
AG
108
Algert Global
San Francisco,
California
| – | -$99K | -729 | Closed |
|
|
ECM
109
ExodusPoint Capital Management
New York
| – | -$89K | -659 | Closed |
|
|
VCA
110
Verdence Capital Advisors
Hunt Valley,
Maryland
| – | -$77K | -567 | Closed |
|
111
HSBC Holdings
London,
United Kingdom
| – | -$56K | -415 | Closed |
|
|
KWM
112
Kingsview Wealth Management
Grants Pass,
Oregon
| – | -$50K | -370 | Closed |
|
|
VFA
113
Valeo Financial Advisors
Carmel,
Indiana
| – | -$2K | -17 | Closed |
|
RNAC Hedge Fund Activity: Q2 2021 in Review
101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2021, worth a combined $219M — down 11% from $245M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RNAC positions and 15 closed out — a net gain of 3 holders — while 38 added to existing stakes and 29 trimmed.
The largest buyer was Cetera Advisors, adding an estimated $2.83M. The largest seller was Polaris Venture Management Co V, exiting entirely with an estimated $12.6M sold.
- 101 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2021, up from 98 in Q1 2021.
- Funds reported $219M of Cartesian Therapeutics stock for Q2 2021, down 11% quarter-over-quarter.
- 18 funds opened new Cartesian Therapeutics positions in Q2 2021 and 15 closed out, a net change of +3 holders.
- The largest Cartesian Therapeutics buyer in Q2 2021 was Cetera Advisors, an estimated $2.83M added.
- The largest Cartesian Therapeutics seller in Q2 2021 was Polaris Venture Management Co V, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2021.